WO2006133353A3 - Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics - Google Patents

Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics Download PDF

Info

Publication number
WO2006133353A3
WO2006133353A3 PCT/US2006/022268 US2006022268W WO2006133353A3 WO 2006133353 A3 WO2006133353 A3 WO 2006133353A3 US 2006022268 W US2006022268 W US 2006022268W WO 2006133353 A3 WO2006133353 A3 WO 2006133353A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
methods
cell survival
neural cell
facilitating neural
Prior art date
Application number
PCT/US2006/022268
Other languages
French (fr)
Other versions
WO2006133353A2 (en
Inventor
Frank M Longo
Stephen M Massa
Original Assignee
Univ North Carolina
Univ California
U S Government Represented By
Frank M Longo
Stephen M Massa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Univ California, U S Government Represented By, Frank M Longo, Stephen M Massa filed Critical Univ North Carolina
Priority to EP06784665A priority Critical patent/EP1893192A4/en
Priority to JP2008515915A priority patent/JP5461009B2/en
Publication of WO2006133353A2 publication Critical patent/WO2006133353A2/en
Publication of WO2006133353A3 publication Critical patent/WO2006133353A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Abstract

Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.
PCT/US2006/022268 2005-06-08 2006-06-08 Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics WO2006133353A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06784665A EP1893192A4 (en) 2005-06-08 2006-06-08 Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics
JP2008515915A JP5461009B2 (en) 2005-06-08 2006-06-08 Method for promoting neuronal cell survival using non-peptide and peptide BDNF neurotrophin analogues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68876705P 2005-06-08 2005-06-08
US60/688,767 2005-06-08

Publications (2)

Publication Number Publication Date
WO2006133353A2 WO2006133353A2 (en) 2006-12-14
WO2006133353A3 true WO2006133353A3 (en) 2009-04-30

Family

ID=37499118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/022268 WO2006133353A2 (en) 2005-06-08 2006-06-08 Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics

Country Status (5)

Country Link
US (2) US8686045B2 (en)
EP (3) EP1893192A4 (en)
JP (1) JP5461009B2 (en)
ES (1) ES2569881T3 (en)
WO (1) WO2006133353A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2248899B8 (en) 2003-03-19 2015-07-15 Biogen MA Inc. NOGO receptor binding protein
AU2005258335B2 (en) 2004-06-24 2011-03-17 Biogen Ma Inc. Treatment of conditions involving demyelination
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
EP2594318B1 (en) * 2005-04-15 2020-06-10 University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
US8686045B2 (en) 2005-06-08 2014-04-01 The University Of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
MX2008000253A (en) 2005-07-08 2008-04-02 Biogen Idec Inc Sp35 antibodies and uses thereof.
CN101605556A (en) * 2006-12-20 2009-12-16 瑞纳神经科学公司 The TRKB agonist of treatment autoimmune disease
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
EP2217697B1 (en) * 2007-11-08 2015-06-10 Biogen MA Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
US20110217280A1 (en) * 2007-12-19 2011-09-08 Vollrath Benedikt Methods for treating neuropsychiatric conditions
US20100317715A1 (en) * 2007-12-21 2010-12-16 Vollrath Benedikt Methods for treating neuropsychiatric conditions
DK2982695T3 (en) 2008-07-09 2019-05-13 Biogen Ma Inc COMPOSITIONS CONCERNING ANTIBODIES AGAINST LINGO OR FRAGMENTS THEREOF
WO2010132999A1 (en) 2009-05-21 2010-11-25 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
KR101138048B1 (en) 2009-11-06 2012-04-23 성균관대학교산학협력단 Novel peptides upregulating BDNF expression and pharmaceutical composition for protection and therapy against Alzheimer's disease and Parkinson's disease comprising the same
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
ES2712752T3 (en) 2009-11-12 2019-05-14 Pharmatrophix Inc Crystalline forms of neurotrophin mimetic compounds and their salts
AU2010329847A1 (en) 2009-12-11 2012-07-26 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
WO2011150347A2 (en) * 2010-05-28 2011-12-01 Pharmatrophix Non-peptide bdnf neurotrophin mimetics
JP2015518829A (en) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． LINGO-2 antagonist for treatment of conditions involving motor neurons
JP6120311B2 (en) * 2013-02-12 2017-04-26 学校法人銀杏学園 Polyphenol compounds
CN105189449A (en) * 2013-03-15 2015-12-23 特罗菲克斯制药股份有限公司 Non-peptide BDNF neurotrophin mimetics
RU2015141934A (en) * 2013-03-15 2017-04-20 Фарматрофикс, Инк. NEPEPTIDE MIMETICS OF NEUROTROPHINE BDNF
CA2909273A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating hcv
AU2015370004B2 (en) 2014-12-26 2021-03-11 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
MX2017009038A (en) 2015-01-08 2017-10-25 Biogen Ma Inc Lingo-1 antagonists and uses for treatment of demyelinating disorders.
EA201792261A1 (en) 2015-05-29 2018-04-30 Зе Боард Оф Трастис Оф Зе Лилэнд Стэнфорд Джуниор Юниверсити NUCLEOSIDE SUBSTANCES TO REDUCE THE HARMFUL ACTIVITY OF GENES CONTAINING EXTENDED NUCLEOTID REPEATERS
JP6923509B2 (en) 2015-07-28 2021-08-18 オトノミ—，インク． Treatment with truncated TRKB and TRKC antagonists
CN108602775B (en) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 Mast cell modulators and uses thereof
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211982A1 (en) * 2000-01-18 2003-11-13 Saragovi Horacio Uri Beta turn peptidomimetic cyclic compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2109262A5 (en) * 1970-10-08 1972-05-26 Inst Francais Du Petrole
US3953416A (en) * 1971-12-20 1976-04-27 Karl Folkers Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same
JPS5025442B2 (en) * 1972-03-14 1975-08-23
DE2343037A1 (en) * 1973-08-25 1975-03-06 Hoechst Ag MEDICINAL PRODUCTS WITH ANTIDEPRESSIVE EFFECT
HU185535B (en) * 1982-05-25 1985-02-28 Mta Koezponti Hivatala Process for preparing new gonadoliberin derivatives
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
GB9402331D0 (en) * 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
WO1996016980A1 (en) 1994-11-29 1996-06-06 Novartis Ag Morpholinoethylamide derivatives
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
WO1999007874A1 (en) * 1996-06-13 1999-02-18 Itoham Foods Inc. Process for producing lh-rh derivatives
CA2338968C (en) * 1998-07-30 2010-04-27 Michael J. Coghlan Glucocorticoid-selective agents
ES2331743T3 (en) * 1999-03-17 2010-01-14 University Of North Carolina At Chapel Hill METHOD OF CREDITING OF CANDIDATE COMPOUNDS FOR SUSCEPTIBILITY TO BILIAR EXCRETION.
US6583148B1 (en) * 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
WO2002060867A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
EP1553964A4 (en) 2002-09-25 2009-08-12 Georgia Tech Res Inst Ketoamide inhibitors in chronic nerve disease
EP2594318B1 (en) 2005-04-15 2020-06-10 University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
US8686045B2 (en) 2005-06-08 2014-04-01 The University Of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211982A1 (en) * 2000-01-18 2003-11-13 Saragovi Horacio Uri Beta turn peptidomimetic cyclic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LONGO ET AL.: "Neurotrophin Small Molecule Mimetics: Candidate Therapeutic Agents for Neurological Disorders.", CURR. MED. CHEM., vol. 5, no. 1, 2005, pages 29 - 41, XP008125095 *

Also Published As

Publication number Publication date
JP5461009B2 (en) 2014-04-02
US20070060526A1 (en) 2007-03-15
EP2581440B1 (en) 2016-03-16
US9604907B2 (en) 2017-03-28
EP2526942B1 (en) 2017-08-09
US20140200277A1 (en) 2014-07-17
EP2526942A3 (en) 2013-07-17
EP1893192A4 (en) 2010-03-31
JP2008545793A (en) 2008-12-18
EP2581440A2 (en) 2013-04-17
ES2569881T3 (en) 2016-05-12
WO2006133353A2 (en) 2006-12-14
EP2526942A2 (en) 2012-11-28
EP2581440A3 (en) 2013-06-26
US8686045B2 (en) 2014-04-01
EP1893192A2 (en) 2008-03-05

Similar Documents

Publication Publication Date Title
WO2006133353A3 (en) Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics
WO2006113097A3 (en) Methods of facilitating cell survival using neurotrophin mimetics
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
WO2007095586A3 (en) Neuronal pain pathway modulators
WO2011150347A3 (en) Non-peptide bdnf neurotrophin mimetics
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
WO2006034373A8 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
WO2006023359A3 (en) Selective vpac2 receptor peptide agonists
WO2006131951A3 (en) MOLECULES THAT ARE ABLE TO INHIBIT THE BINDING BETWEEN NGF AND THE TrkA RECEPTOR AS ANALGESICS WITH PROLONGED EFFECT
WO2006052608A3 (en) Treatment of obesity and related disorders
WO2006037016A3 (en) Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
WO2008051797A3 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
WO2006020060A3 (en) Iap binding compounds
WO2005115439A3 (en) Cerberus/coco derivatives and uses thereof
WO2007045927A3 (en) Therapeutic agent
IL189008A0 (en) Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
WO2003026479A3 (en) Methods of suppressing microglial activation
ZA200802645B (en) Novel azetidine compounds useful in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia
PL1900362T3 (en) Alfa-aminoamide derivatives useful in the treatment of addictive disorders
WO2008080045A3 (en) Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders
WO2007030761A3 (en) Acyclic 1,4-diamines and uses thereof
EP2476681A3 (en) Amino-aza-adamantane derivatives and methods of use
PL1972637T3 (en) huTNFR1 selective antagonists
WO2003047514A3 (en) Reducing myelin-mediated inhibition of axon regeneration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008515915

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006784665

Country of ref document: EP